Sotalol Side Effects
Sotalol's most serious side effect is QT prolongation leading to torsades de pointes, a potentially fatal ventricular arrhythmia, while the most common side effects are fatigue, bradycardia, shortness of breath, and dizziness.
Serious/Life-Threatening Side Effects
QT Prolongation and Proarrhythmia
- Torsades de pointes occurs in 1.9-3.5% of patients 1, 2, 3
- Risk increases when QTc exceeds 500 ms or increases >25% from baseline 2, 3
- Higher risk groups include:
Bradycardia and Conduction Abnormalities
- Significant bradycardia requiring discontinuation occurs in 5.9% of patients 4
- May require permanent pacing in severe cases (occurred in 4 of 11 patients with significant bradycardia in one study) 5
- Particularly problematic in Fontan patients with congenital heart disease 5
- Cardiac asystole reported in massive overdose 6
Ventricular Arrhythmias
- Ventricular tachycardia and premature ventricular complexes reported in overdose 6
- Proarrhythmic risk higher in patients with advanced heart failure 1
Common Side Effects
Beta-Blocker Related Effects
The side effect profile is similar to other beta-blockers with added QT prolongation risk 1:
- Fatigue (most common reason for discontinuation) 6, 5, 7
- Dyspnea/shortness of breath 6, 5, 7
- Dizziness 6
- Hypotension (especially in overdose or with reduced cardiac function) 4, 6
Discontinuation Rates
- Overall discontinuation rate: 23.5% at 1 year (higher than other beta-blockers at 5.3%) 1
- Discontinuation due to side effects: 16-18% 5, 7
- Most discontinuations occur within the first month of therapy 8
Important Clinical Considerations
Monitoring Requirements
Mandatory monitoring includes 4, 6:
- Daily QT interval measurement from 12-lead ECG during initiation
- Must be started in monitored setting
- ECG at baseline and 48-72 hours after outpatient initiation 3
- Careful monitoring for QT prolongation and abnormal TU waves 2
When to Stop or Reduce Dose
Discontinue or reduce sotalol if 2:
- QTc reaches >500 ms
- QTc increases >25% from baseline
- Development of new fast heartbeats with lightheadedness/fainting 6
Drug Interactions
Avoid concomitant use with other QT-prolonging medications, as this increases torsades de pointes risk 6
Special Populations
Use with extreme caution or avoid in 1, 3:
- Severe heart failure (LVEF <20% or NYHA Class III/IV)
- Severe renal impairment (CrCl <40 mL/min)
- Pre-existing QT prolongation
- Congenital heart disease, especially Fontan patients 5
Late-Onset Effects
Important caveat: QT prolongation can occur late in therapy, with cases reported after >3 years of treatment 8. This highlights the need for ongoing vigilant surveillance throughout the duration of sotalol therapy, not just during initiation.